S&P Global, the world’s leading authority of ESG ratings and research, recently released “The S&P Global Sustainability Yearbook 2026.” Microbio Group delivered an outstanding performance: its subsidiary Oneness Biotech Co., Ltd. (4743) has been selected for the fourth consecutive year, while Diamond BioFund Inc. (6901) and Microbio Co., Ltd. (4128) made their debut on the list this year thanks to their exceptional ESG achievements. The simultaneous inclusion of three group companies not only demonstrates Microbio Group’s commitment to sustainable operations but also sets a new international ESG benchmark for Taiwan’s biotechnology and biotech investment industry.

The S&P Global Sustainability Yearbook is one of the world’s most credible sustainability assessments, based on data from the Corporate Sustainability Assessment (CSA). Each year, it rigorously evaluates over 9,200 companies across nearly 60 industries on Environmental (E), Social (S), and Governance (G) criteria. Only top performers—those ranking in the top 15% of their industry and within 30% of the industry leader’s score—earn the honor of being included. Inclusion in the Yearbook signifies that a company has demonstrated excellence and consistency in sustainable governance, risk management, operational resilience, and transparency, proving its world-class competitiveness in sustainability.

Kuo Hsien-Shou, Chairman of Oneness Biotech Co., Ltd., stated: “Being selected for the S&P Global Sustainability Yearbook for the fourth consecutive year is more than just an honor; it is a profound validation of our integrity in governance and our commitment to R&D innovation. Compared to global peers in the S&P Pharmaceuticals category, Oneness Biotech delivered an exceptional performance in the Governance & Economic and Social dimensions this year. Notably, our scores in ‘Risk & Crisis Management’ saw a significant leap, reflecting our resilience in response to the dynamic biotechnology sector. Furthermore, achieving perfect scores in key indicators such as ‘Innovation Management’ and ‘Customer Relations’ underscores our patient-centric core values and our pursuit of scientific breakthroughs. With transparent governance as our foundation, Oneness Biotech will continue to translate innovative research into tangible health and social well-being.”

Chen Tzen-Wen, Chairman of Microbio Co., Ltd., remarked: “At Microbio, we drive ESG from the top down through our Board-level Sustainability Committee. Over the past two years, we have extended our sustainable information disclosure, management, and sustainable actions to our subsidiaries, Cotton Field Organic Co., Ltd. and Microbio (Shanghai) Co., Ltd. These efforts include projects such as energy conservation at logistics center, packaging material management, and solar energy assessments. Given our diverse operations spanning R&D and sales of new drugs, medical devices, and health products, as well as organic retail, S&P Global categorizes Microbio within the Personal Products industry. Among the 24 assessment categories in this sector, Microbio ranked in the global top 10% in 14 categories, achieving perfect scores in ‘Transparency & Reporting’ and ‘Product Quality & Recall Management’. Inclusion in the Sustainability Yearbook is the greatest encouragement for our team. Furthermore, Microbio is the first and only Taiwanese company to be included in the Yearbook for this specific industry, demonstrating international recognition of our efforts in corporate governance, environmental stewardship, and social inclusivity.”

Pan-Chyr Yang, Chairman of Diamond BioFund Inc., stated: “Our inclusion in the 2026 S&P Global Sustainability Yearbook, ranking in the global top 10% of the Diversified Financial Services and Capital Markets industry, highlights our leadership in sustainable governance. With ‘Responsible Investment’ at the core of our strategy, we have institutionalized ESG assessment and risk management, fully integrating them into our investment evaluation, decision-making, and post-investment management processes. This robust framework enhances our decision quality and strengthens risk control, laying a solid foundation for the long-term, steady growth of our portfolio. Among 12 assessment categories, 10 ranked within the global top 5%, with perfect scores in ‘Transparency & Reporting’ and ‘Tax Strategy,’ and outstanding performances in ‘Materiality Management,’ ‘Risk & Crisis Management,’ and ‘Sustainable Finance’. These results reaffirm that sustainable governance is deeply embedded in our investment decision-making and post-investment management, and reflect our strong execution and effective delivery of our long-term strategy.”

The simultaneous inclusion of three Microbio Group companies in the Sustainability Yearbook signifies that the Group has fully aligned with international standards, from “R&D and Manufacturing” to “Biotech Investment”. Moving forward, Microbio Group will continue to leverage its influence, combining scientific innovation with ESG strategies to protect public health and collaborate with our stakeholders toward a low-carbon and sustainable future.